TP53 and metastatic neoplasm: In addition, we found MYC pathway alterations were enriched in patients with BM development compared to patients without metastatic disease, and TP53 and DNA damage repair pathway alterations were significantly enriched in those with BM and EM compared to patients without metastatic disease (Suppl.